



US00D905788S

(12) **United States Design Patent** (10) **Patent No.:** **US D905,788 S**  
**Kumar et al.** (45) **Date of Patent:** **\*\* Dec. 22, 2020**

(54) **LABEL**

*Primary Examiner* — Mary Ann Calabrese

(71) Applicant: **Sun Pharmaceutical Industries Limited**, Maharashtra (IN)

*Assistant Examiner* — Catherine Ho

(74) *Attorney, Agent, or Firm* — Liang & Hennessey LLP; Stanley D. Liang

(72) Inventors: **Samarth Kumar**, Baroda (IN); **Prashant Kane**, Baroda (IN); **Mark Hagler**, Princeton, NJ (US); **Kartik Nagar**, Baroda (IN); **Sapna Fadnis**, Baroda (IN); **Raman Lad**, Baroda (IN); **Subhas Balaram Bhowmick**, Baroda (IN)

(57) **CLAIM**

The ornamental design for a label, as shown and described.

**DESCRIPTION**

(73) Assignee: **Sun Pharmaceutical Industries Limited**, Mumbai (IN)

The patent or application file contains a least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.

(\*\*) Term: **15 Years**

(21) Appl. No.: **29/679,413**

FIG. 1 is a front view of the first embodiment of a label, showing our new design.

(22) Filed: **Feb. 5, 2019**

FIG. 2 is a front view of the second embodiment of a label, showing our new design.

(51) **LOC (12) Cl.** ..... **19-08**

FIG. 3 is a front view of a third embodiment of a label, showing our new design.

(52) **U.S. Cl.**

USPC ..... **D20/27**

FIG. 4 is a front view of a fourth embodiment of a label, showing our new design.

(58) **Field of Classification Search**

USPC ..... D9/550, 563; D10/46, 47, 52, 104.1, D10/104.2; D14/490, 491; D19/1, 2, 3, D19/4, 5, 6, 7, 8, 9, 10, 11, 12; D20/10, D20/11, 18, 22, 23, 24, 25, 26, 27, 28, D20/29, 40, 43, 44, 49

FIG. 5 is a front view of a fifth embodiment of a label, showing our new design.

CPC ..... G09F 1/00; G09F 1/04; G09F 3/00; G09F 3/005; G09F 3/0288; G09F 3/0289; G09F 3/02; G09F 3/04; G09F 3/06; G09F 3/08; G09F 3/10; G06K 19/0776

FIG. 6 is a front view of a sixth embodiment of a label, showing our new design.

See application file for complete search history.

FIG. 7 is a front view of a seventh embodiment of a label, showing our new design.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

D593,613 S \* 6/2009 Langan ..... D20/27  
D595,361 S \* 6/2009 Langan ..... D20/22  
D597,608 S \* 8/2009 Langan ..... D20/27

FIG. 8 is a front view of an eighth embodiment of a label, showing our new design.


FIG. 9 is a front view of a ninth embodiment of a label, showing our new design; and,

FIG. 10 is a front view of a tenth embodiment of a label, showing our new design.

The broken lines showing wording, symbols, barcodes, trademarks, and boxes are environment only and form no part of the claimed design.

**1 Claim, 10 Drawing Sheets**  
**(10 of 10 Drawing Sheet(s) Filed in Color)**

(Continued)



(56)

**References Cited**

U.S. PATENT DOCUMENTS

|              |    |   |         |        |       |                     |
|--------------|----|---|---------|--------|-------|---------------------|
| D607,941     | S  | * | 1/2010  | Langan | ..... | D20/27              |
| D621,879     | S  | * | 8/2010  | Langan | ..... | D20/27              |
| D624,595     | S  | * | 9/2010  | Langan | ..... | D20/27              |
| D624,596     | S  | * | 9/2010  | Langan | ..... | D20/27              |
| D633,151     | S  | * | 2/2011  | Langan | ..... | D20/27              |
| D634,368     | S  | * | 3/2011  | Langan | ..... | D20/27              |
| D639,861     | S  | * | 6/2011  | Langan | ..... | D20/27              |
| D639,862     | S  | * | 6/2011  | Langan | ..... | D20/27              |
| D639,863     | S  | * | 6/2011  | Langan | ..... | D20/27              |
| D643,469     | S  | * | 8/2011  | Langan | ..... | D20/27              |
| D643,471     | S  | * | 8/2011  | Langan | ..... | D20/27              |
| D643,472     | S  | * | 8/2011  | Langan | ..... | D20/27              |
| D645,094     | S  | * | 9/2011  | Langan | ..... | D20/27              |
| D649,196     | S  | * | 11/2011 | Langan | ..... | D20/27              |
| D785,710     | S  | * | 5/2017  | Lin    | ..... | D20/27              |
| D785,711     | S  | * | 5/2017  | Lin    | ..... | D20/27              |
| 2012/0000592 | A1 | * | 1/2012  | Mase   | ..... | G09F 3/02<br>156/60 |

\* cited by examiner

TO OPEN: Tear at notch at bottom of overwrap.  
 Do not remove unit from overwrap until ready to use.  
 Do not use if overwrap has been previously open or damaged.  
 The overwrap is a moisture and oxygen barrier.

NDC 62758-073-60 Rx only

**Infugem™**  
**Gemcitabine**  
 in 0.9% sodium chloride injection

**1,200 mg** per 120 mL  
 (10 mg/mL)


**Caution: Cytotoxic Agent** For Intravenous Use Only


Contains one sterile single dose bag.

Each 100 mL contains:  
 Gemcitabine 1,000 mg  
 equivalent to Gemcitabine HCl USP 1,136 mg  
 Sodium Chloride 900 mg  
 Hydrochloric acid and  
 Sodium hydroxide added to adjust pH q.s.

Premixed Intravenous Solution  
 Usual Dosage: See prescribing information.

Do NOT remove or add medication to IV bag.  
 Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).  
 [see USP Controlled Room Temperature].  
 Do not freeze.

  
 SUN  
PHARMA

  
 OTHER

P3B001  
 6U/3H/108/25-01/VP-6

|  |   |
|--|---|
| Distributed by:<br>Sun Pharmaceutical Industries, Inc.<br>Cranbury, NJ 08512 | Lot No. <span style="border: 1px solid black; display: inline-block; width: 100px; height: 15px;"></span> |
| Manufactured by:<br>Sun Pharmaceutical Industries, Inc., India               | EXP. <span style="border: 1px solid black; display: inline-block; width: 100px; height: 15px;"></span>    |

FIG. 1

TO OPEN: Tear at notch at bottom of overwrap.  
 Do not remove unit from overwrap until ready to use.  
 Do not use if overwrap has been previously open or damaged.  
 The overwrap is a moisture and oxygen barrier.

NDC 62758-073-60 Rx only

**Infugem™**  
**Gemcitabine**  
 in 0.9% sodium chloride injection

**1,300 mg** per 130 mL  
 (10 mg/mL)


**Caution: Cytotoxic Agent** For Intravenous Use Only

Contains one sterile single dose bag.


Each 100 mL contains:  
 Gemcitabine 1,000 mg  
 equivalent to Gemcitabine HCl USP 1,136 mg  
 Sodium Chloride 900 mg  
 Hydrochloric acid and  
 Sodium hydroxide added to adjust pH: q.s.

Premixed Intravenous Solution  
 Usual Dosage: See prescribing information.


Do NOT remove or add medication to IV bag.  
 Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).  
 [see USP Controlled Room Temperature].  
 Do not freeze.



SUN  
PHARMA



OTHER



|  |   |
|--|---|
| Distributed by:<br>Sun Pharmaceutical Industries, Inc.<br>Cranbury, NJ 08512 | P130001<br>6UJ3H1G82S-01VP-6<br>Lot No. <span style="border: 1px solid black; display: inline-block; width: 80px; height: 15px;"></span><br>EXP. <span style="border: 1px solid black; display: inline-block; width: 80px; height: 15px;"></span> |
| Manufactured by:<br>Sun Pharmaceutical Industries, Inc., India               |   |

FIG. 2

TO OPEN: Tear at notch at bottom of overwrap.  
Do not remove unit from overwrap until ready to use.  
Do not use if overwrap has been previously open or damaged.  
The overwrap is a moisture and oxygen barrier.

NDC 62758-073-60 Rx only

**Infugem<sup>TM</sup>**  
**Gemcitabine**  
in 0.9% sodium chloride injection

**1,400 mg** per 140 mL  
(10 mg/mL)


**Caution: Cytotoxic Agent** For Intravenous Use Only

Contains one sterile single dose bag.


Each 100 mL contains:  
Gemcitabine 1,000 mg  
equivalent to Gemcitabine HCl USP 1,136 mg  
Sodium Chloride 900 mg  
Hydrochloric acid and  
Sodium hydroxide added to adjust pH: q.s.

Premixed Intravenous Solution  
Usual Dosage: See prescribing information.


Do NOT remove or add medication to IV bag.  
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).  
[see USP Controlled Room Temperature].  
Do not freeze.



SUN  
Pharma



OTHER



0200

|   |                             |
|---|-----------------------------|
| Distributed by:<br>Sun Pharmaceutical Industries, Inc.<br>Crantbury, NJ 08512 | PUB001<br>SUNPH10826-01VP-6 |
| Manufactured by:<br>Sun Pharmaceutical Industries, Inc., India                | Lot No.<br>EXP.             |

**FIG. 3**

TO OPEN: Tear at notch at bottom of overwrap.  
Do not remove unit from overwrap until ready to use.  
Do not use if overwrap has been previously open or damaged.  
The overwrap is a moisture and oxygen barrier.

NDC 62758-073-60 Rx only

**Infugem™**  
**Gemcitabine**  
in 0.9% sodium chloride injection

**1,500 mg** per 150 mL  
(10 mg/mL)


**Caution: Cytotoxic Agent** For Intravenous Use Only

Contains one sterile single dose bag.


Each 100 mL contains:  
Gemcitabine 1,000 mg  
equivalent to Gemcitabine HCl USP 1,136 mg  
Sodium Chloride 900 mg  
Hydrochloric acid and  
Sodium hydroxide added to adjust pH: q.s.

Premixed Intravenous Solution  
Usual Dosage: See prescribing information.


Do NOT remove or add medication to IV bag.  
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).  
[see USP Controlled Room Temperature].  
Do not freeze.



SUN  
Pharma



OTHER



PNB001  
6UJ3H19828-01VP-6

|   |                 |
|---|-----------------|
| Distributed by:<br>Sun Pharmaceutical Industries, Inc.<br>Crantbury, NJ 08512 | Lot No.<br>EXP. |
| Manufactured by:<br>Sun Pharmaceutical Industries, Inc., India                |                 |

FIG. 4

TO OPEN: Tear at notch at bottom of overwrap.  
Do not remove unit from overwrap until ready to use.  
Do not use if overwrap has been previously open or damaged.  
The overwrap is a moisture and oxygen barrier.

NDC 62758-073-60 Rx only

**Infugem<sup>TM</sup>**  
**Gemcitabine**  
in 0.9% sodium chloride injection

**1,600 mg** per 160 mL  
(10 mg/mL)


**Caution: Cytotoxic Agent** For Intravenous Use Only

Contains one sterile single dose bag.


Each 100 mL contains:  
Gemcitabine 1,000 mg  
equivalent to Gemcitabine HCl USP 1,136 mg  
Sodium Chloride 900 mg  
Hydrochloric acid and  
Sodium hydroxide added to adjust pH: q.s.

Premixed Intravenous Solution  
Usual Dosage: See prescribing information.


Do NOT remove or add medication to IV bag.  
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).  
[see USP Controlled Room Temperature].  
Do not freeze.



SUN  
Pharma



OTHER



0200

|   |                             |
|---|-----------------------------|
| Distributed by:<br>Sun Pharmaceutical Industries, Inc.<br>Crantbury, NJ 08512 | PUB001<br>SUNPH10828-01VP-6 |
| Manufactured by:<br>Sun Pharmaceutical Industries, Inc., India                | Lot No.<br>EXP.             |

FIG. 5

TO OPEN: Tear at notch at bottom of overwrap.  
Do not remove unit from overwrap until ready to use.  
Do not use if overwrap has been previously open or damaged.  
The overwrap is a moisture and oxygen barrier.

NDC 62758-073-60 Rx only

**Infugem™**  
**Gemcitabine**  
in 0.9% sodium chloride injection

**1,700 mg** per 170 mL  
(10 mg/mL)



Caution: Cytotoxic Agent For Intravenous Use Only

Contains one sterile single dose bag.

Each 100 mL contains:  
Gemcitabine 1,000 mg  
equivalent to Gemcitabine HCl USP 1,136 mg  
Sodium Chloride 900 mg  
Hydrochloric acid and  
Sodium hydroxide added to adjust pH: q.s.

Premixed Intravenous Solution  
Usual Dosage: See prescribing information.

Do NOT remove or add medication to IV bag.  
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).  
[see USP Controlled Room Temperature].  
Do not freeze.

   
SUN OTHER

Distributed by: Sun Pharmaceutical Industries, Inc.  
Crantbury, NJ 08512  
Manufactured by: Sun Pharmaceutical Industries, Inc., India

FJBE001  
SUNPH10828-01VP-6  
Lot No. \_\_\_\_\_  
EXP. \_\_\_\_\_




FIG. 6



TO OPEN: Tear at notch at bottom of overwrap.  
Do not remove unit from overwrap until ready to use.  
Do not use if overwrap has been previously open or damaged.  
The overwrap is a moisture and oxygen barrier.

NDC 62756-073-60 Rx only

**Infugem™**  
**Gemcitabine**  
in 0.9% sodium chloride injection

**1,800 mg** per 180 mL  
(10 mg/mL)


**Caution: Cytotoxic Agent** For Intravenous Use Only

Contains one sterile single dose bag.


Each 180 mL contains:  
Gemcitabine 1,800 mg  
equivalent to Gemcitabine HCl USP 1,136 mg  
Sodium Chloride 900 mg  
Hydrochloric acid and  
Sodium hydroxide added to adjust pH. q.s.

Prepared Intravenous Solution  
Usual Dosage: See prescribing information.


Do NOT remove or add medication to IV bag.  
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).  
[see USP Controlled Room Temperature].  
Do not freeze.



SUN  
PHARMA



GREEN



22041

|  |                                |
|--|--------------------------------|
| Distributed by:<br>Sun Pharmaceutical Industries, Inc.<br>Cranbury, NJ 08512 | FJ20001<br>GUSDRUGS/28-01.VF-6 |
| Manufactured by:<br>Sun Pharmaceutical Industries, Inc., India               | Lot No.<br>EXP.                |

**FIG. 7**

TO OPEN: Tear at notch at bottom of overwrap.  
 Do not remove unit from overwrap until ready to use.  
 Do not use if overwrap has been previously open or damaged.  
 The overwrap is a moisture and oxygen barrier.

NDC 62758-073-60 Rx only

**Infugem™**  
**Gemcitabine**  
 in 0.9% sodium chloride injection

**1,900 mg** per 190 mL  
 (10 mg/mL)


**Caution: Cytotoxic Agent** For Intravenous Use Only

Contains one sterile single dose bag.


Each 100 mL contains:  
 Gemcitabine 1,000 mg  
 equivalent to Gemcitabine HCl USP 1,136 mg  
 Sodium Chloride 900 mg  
 Hydrochloric acid and  
 Sodium hydroxide added to adjust pH: q.s.

Premixed Intravenous Solution  
 Usual Dosage: See prescribing information.


Do NOT remove or add medication to IV bag.  
 Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).  
 [see USP Controlled Room Temperature].  
 Do not freeze.



SUN  
PHARMA



OTHER



|  |  |
|--|--|
| Distributed by:<br>Sun Pharmaceutical Industries, Inc.<br>Cranbury, NJ 08512 | P3E001<br>3U3GH19828-01VP-6<br>Lot No. _____<br>EXP. _____ |
| Manufactured by:<br>Sun Pharmaceutical Industries, Inc., India               |  |

FIG. 8

TO OPEN: Tear at notch at bottom of overwrap.  
Do not remove unit from overwrap until ready to use.  
Do not use if overwrap has been previously open or damaged.  
The overwrap is a moisture and oxygen barrier.

NDC 62758-746-60 Rx only

**Infugem™**  
**Gemcitabine**  
in 0.9% sodium chloride injection

**2,000 mg** per 200 mL  
(10 mg/mL)



Caution: Cytotoxic Agent For Intravenous Use Only

Contains one sterile single dose bag.

Each 100 mL contains:  
Gemcitabine 1,000 mg  
equivalent to Gemcitabine HCl USP 1,136 mg  
Sodium Chloride 300 mg  
Hydrochloric acid and  
Sodium hydroxide added to adjust pH: q.s.

Premixed Intravenous Solution  
Usual Dosage: See prescribing information.

Do NOT remove or add medication to IV bag.  
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).  
[see USP Controlled Room Temperature].  
Do not freeze.

   
SUN OTHER

Distributed by: Sun Pharmaceutical Industries, Inc.  
Crantbury, NJ 08512  
Manufactured by: Sun Pharmaceutical Industries, Inc., India

FJBE001  
SUN/01108/25-01/VP-6  
Lot No. EXP.

62758-746-60

FIG. 9

TO OPEN: Tear at notch at bottom of overwrap.  
Do not remove unit from overwrap until ready to use.  
Do not use if overwrap has been previously open or damaged.  
The overwrap is a moisture and oxygen barrier.

NDC 62758-974-60 Rx only

**Infugem™**  
**Gemcitabine**  
in 0.9% sodium chloride injection

**2,200 mg** per 220 mL  
(10 mg/mL)


**Caution: Cytotoxic Agent** For Intravenous Use Only


Contains one sterile single dose bag.


Each 100 mL contains:  
Gemcitabine 1,000 mg  
equivalent to Gemcitabine HCl USP 1,135 mg  
Sodium Chloride 900 mg  
Hydrochloric acid and  
Sodium hydroxide added to adjust pH. q.s.

Premixed Intravenous Solution  
Usual Dosage: See prescribing information.

Do NOT remove or add medication to IV bag.  
Store at 20°C to 25°C (68°F to 77°F);  
excursions permitted between 15°C and 30°C (59°F and 86°F).  
[see USP Controlled Room Temperature].  
Do not freeze.

  
**SUN**  
PHARMA

  
**ORTAK**

  
62758-974-60  
3330

Distributed by:  
Sun Pharmaceutical Industries, Inc.  
Cranbury, NJ 08812

Manufactured by:  
Sun Pharmaceutical Industries, Inc., India

P325001  
QUADRU68/28-01.VF-6

Lot No.  
EXP.

FIG. 10